Correlation Between Com7 PCL and Mega Lifesciences

Can any of the company-specific risk be diversified away by investing in both Com7 PCL and Mega Lifesciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Com7 PCL and Mega Lifesciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Com7 PCL and Mega Lifesciences Public, you can compare the effects of market volatilities on Com7 PCL and Mega Lifesciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Com7 PCL with a short position of Mega Lifesciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Com7 PCL and Mega Lifesciences.

Diversification Opportunities for Com7 PCL and Mega Lifesciences

0.45

Correlation Coefficient

Com7 PCL  Mega Lifesciences

Very weak diversification

The 3 months correlation between Com7 and Mega is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding Com7 PCL and Mega Lifesciences Public in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mega Lifesciences Public and Com7 PCL is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Com7 PCL are associated (or correlated) with Mega Lifesciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mega Lifesciences Public has no effect on the direction of Com7 PCL i.e., Com7 PCL and Mega Lifesciences go up and down completely randomly.

Pair Corralation between Com7 PCL and Mega Lifesciences

Assuming the 90 days trading horizon Com7 PCL is expected to generate 1.02 times more return on investment than Mega Lifesciences. However, Com7 PCL is 1.02 times more volatile than Mega Lifesciences Public. It trades about 0.08 of its potential returns per unit of risk. Mega Lifesciences Public is currently generating about 0.04 per unit of risk. If you would invest  1,950  in Com7 PCL on April 22, 2025 and sell it today you would earn a total of  180.00  from holding Com7 PCL or generate 9.23% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Com7 PCL  vs.  Mega Lifesciences Public

Com7 PCL

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Com7 PCL are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite quite weak forward-looking signals, Com7 PCL may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Mega Lifesciences Public

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Mega Lifesciences Public are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent forward-looking signals, Mega Lifesciences is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors.

Pair Trading with Com7 PCL and Mega Lifesciences

The main advantage of trading using opposite Com7 PCL and Mega Lifesciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Com7 PCL position performs unexpectedly, Mega Lifesciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mega Lifesciences will offset losses from the drop in Mega Lifesciences' long position.

The idea behind Com7 PCL and Mega Lifesciences Public pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.